Vancomycin mass transfer characteristics of high-flux cellulosic dialysers

被引:26
作者
Scott, MK
Mueller, BA
Clark, WR
机构
[1] Purdue Univ, Sch Pharm & Pharmacal Sci, Dept Pharm Practice, W Lafayette, IN 47907 USA
[2] Baxter Healthcare Corp, Div Renal, McGaw Pk, IL 60085 USA
[3] Indiana Univ, Sch Med, Dept Med, Div Nephrol, Indianapolis, IN USA
关键词
convection; diffusion; haemodialyser; pharmacokinetics; vancomycin;
D O I
10.1093/ndt/12.12.2647
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. In comparison to conventional haemodialysis membranes, highly permeable membranes allow a broader spectrum of solute removal, including enhanced elimination of vancomycin (1448 Daltons). However, the mass transfer characteristics of vancomycin removal by highly permeable membranes have not been adequately assessed. An understanding of vancomycin's predominant dialytic mass transfer mechanism under a given set of operating conditions, including dialyser type and flow rates, may permit more accurate dosing of the drug. Methods. We performed a mass transfer analysis of vancomycin removal by a high-flux dialyser, cellulose triacetate (CT). In a cross-over fashion with a 3-week washout between treatments, eight subjects received vancomycin 1000 mg (1) during the last hour of CT haemodialysis; or (2) after dialysis. Serial urea and vancomycin serum concentrations were used to assess dialytic removal. Results. Dialysis removed 26.2% (mean; range 16-44%) of the administered vancomycin dose. While vancomycin removal and (Kt/V)(urea) were directly correlated (r = 0.88; P < 0.005), no correlation was observed between vancomycin removal and weight-normalized ultrafiltration rate. Conclusions. These findings suggest that for the CT dialyser and dialysis operating conditions employed in this study, vancomycin clearance was primarily mediated by diffusion. As such, these data challenge the general concept that convection is primarily responsible for the removal of solutes in the same molecular weight class as vancomycin during high-flux dialysis.
引用
收藏
页码:2647 / 2653
页数:7
相关论文
共 54 条
[1]  
Alwakeel J., 1994, International Urology and Nephrology, V26, P223, DOI 10.1007/BF02768291
[2]  
Anderstam B, 1996, J AM SOC NEPHROL, V7, P2453
[3]  
[Anonymous], 1995, MMWR Recomm Rep, V44, P1
[4]  
BABB AL, 1975, KIDNEY INT, V7, pS23
[5]  
BABB AL, 1971, T AM SOC ART INT ORG, V17, P81
[6]  
BASTANI B, 1988, DIALYSIS TRANSPLANT, V17, P527
[7]  
BASTANI B, 1988, DIALYSIS TRANSPLANT, V17, P543
[8]  
BASTANI B, 1988, DIALYSIS TRANSPLANT, V17, P528
[9]  
*BAXT HEALTHC CORP, 1988, 5M1546 CT CELL TRIAC
[10]  
BOHLER J, 1992, EUR J CLIN PHARMACOL, V42, P635